Rizatriptan

Synonyms: 利扎曲坦; MK 462 free base
Rizatriptan (MK 462 free base) 是一种口服有效的 5-HT1B/5-HT1D 受体激动剂,可透过血脑屏障,通过收缩颅内及脑外血管并抑制神经肽释放发挥显著的抗偏头痛作用,其代谢具有物种和组织特异性,例如在褐家鼠肝脏中主要由 MAO-A 进行氧化脱氨基代谢,因此禁止与 MAO-A 抑制剂联合给药,此外还可能加重硝酸甘油诱导的皮肤异常性疼痛、延长中枢敏化时间并增加小鼠的焦虑样行为及主动觅药行为,已被广泛应用于偏头痛及药物过度使用性头痛的相关研究。
产品编号: MS-T50625 CAS No.: 144034-80-0 分子式: C15H19N5 分子量: 269.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Rizatriptan (MK 462 free base) 是一种口服有效的 5-HT1B/5-HT1D 受体激动剂,可透过血脑屏障,通过收缩颅内及脑外血管并抑制神经肽释放发挥显著的抗偏头痛作用,其代谢具有物种和组织特异性,例如在褐家鼠肝脏中主要由 MAO-A 进行氧化脱氨基代谢,因此禁止与 MAO-A 抑制剂联合给药,此外还可能加重硝酸甘油诱导的皮肤异常性疼痛、延长中枢敏化时间并增加小鼠的焦虑样行为及主动觅药行为,已被广泛应用于偏头痛及药物过度使用性头痛的相关研究。

生物实验数据

生物活性 Rizatriptan (MK 462 free base) is an orally effective 5-HT1B/5-HT1D receptor agonist that crosses the blood-brain barrier and exerts significant anti-migraine effects by constricting intracranial and extracranial blood vessels and inhibiting neuropeptide release; its metabolism is species- and tissue-specific, for example, it undergoes oxidative deamination primarily by MAO-A in the liver of Rattus norvegicus, so co-administration with MAO-A inhibitors is contraindicated; it may also aggravate nitroglycerin-induced cutaneous allodynia, prolong central sensitization, and increase anxiety-like behavior and active drug-seeking behavior in mice; and it has been widely used in research on migraine and medication-overuse headache.
IC50 & Target

5-HT1D Receptor

 

5-HT1B Receptor

 

体内研究
(In Vivo)

Rizatriptan (0.02 mg/kg;口服;在 NTG 刺激阶段持续至第 14 天) 会加重硝酸甘油 (NTG) 诱导的皮肤异常性疼痛,延长中枢敏化时间,增加类焦虑行为,并促使雌性 C57BL/6J 小鼠产生主动觅药行为,其中前额叶前边缘皮层和三叉神经脊束核尾侧亚核是关键的中枢枢纽脑区。

Animal Model: C57BL/6J (female, 8-10 weeks old, 20-30 g, SPF grade, NTG-induced medication overuse headache model)
Dosage: 0.02 mg/kg
Administration: oral; voluntary free-choice access; during NTG stimulation phase until day 14
Result: Exacerbated NTG-induced cutaneous allodynia, with hind paw mechanical pain thresholds significantly lower than control groups during modeling phase and returning to baseline only by day 40.
Showed a stable, fluctuating upward preference for rizatriptan solution, with consumption ratio to total liquid consistently above 0.5 and significantly higher on days 4, 6, 8, 10, 12, and 14.
Exhibited more rapid decrease in head and hind paw mechanical pain thresholds and slower recovery after SNP stimulation on day 40.
Had significantly lower time in open arms/total time, lower proportion of open arm entries, higher time in closed arms/total time, and higher proportion of closed arm entries.
Had significantly shorter residence time in central zone, shorter freezing time in central zone, shorter activity distance in central zone, and fewer entries into central zone.
Showed significantly increased c-Fos positive cell counts in 25 brain regions.

化学信息

分子量 269.34
分子式 C15H19N5
CAS No. 144034-80-0
别名 利扎曲坦; MK 462 free base

储存&溶解度

溶解度信息
DMSO: 250 mg/mL (928.16 mM), Sonication is recommended.
体内实验配方
10% DMSO+90% Saline: 10 mg/mL (37.13 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础